外螺旋抗体NDT9513727に結合する補完体C5a受容体の構造
Nathan Robertson1, Mathieu Rappas1, Andrew S Doré1
1Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX, UK.
Nature
|January 5, 2018
まとめ
C5aアナフィラトキシン化学反応受容体1 (C5aR1) を標的とする小分子は,新たな治療的可能性を秘めています. 構造分析により,NDT9513727は受容体外で結合していることが判明した.
科学分野:
- 免疫学
- 薬理学について
- 構造生物学
背景:
- 補完体系 特にC5aは 炎症を誘発し セプシスや神経変性などの病気に関与しています
- 現在のC5aアンタゴーニストは,標的外効果と低生物利用性を含む課題に直面しています.
- C5aR1 (CD88) を標的とする小分子阻害剤は有望な治療候補である.
研究 の 目的:
- 小分子C5aR1抗剤の作用メカニズムを解明する.
- 逆アゴニストNDT9513727との複合体におけるC5aR1の構造を決定する.
- NDT9513727の種選択性の構造的根拠を理解する.
主な方法:
- NDT9513727に結合した熱安定化C5aR1 (C5aR1 StaR) のX線結晶図
- 小分子-リガンドの相互作用の構造ベースの分析.
- 種間の結合モードの比較
主要な成果:
- NDT9513727は,トランスメブランヘリックス3,4,5の間のエクストラヘリックスポケットでC5aR1に結合している.
- 残留物 Trp2135.49との重要な相互作用は,種選択性にとって極めて重要である.
- NDT9513727は,このユニークな結合モードを通して逆アゴニストとして機能します.
結論:
- NDT9513727の超螺旋結合モードは,C5aR1での逆アゴニズムを説明する.
- この相互作用を理解することで,より選択的で効果的なC5aR1阻害剤を設計するための洞察が得られます.
- この構造データは,補足媒介性疾患に対する新しい治療法の開発を助長する.
関連する概念動画
Drug-Receptor Interaction: Antagonist
5.1K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.8K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.4K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.4K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.8K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K


